Program
Program of the Symposium
September 3, 2025
Public Health & AI Innovations in Oncology
September 4, 2025
Breakthroughs in Oncology & Oncology Collaboration
September 5, 2025
Emerging Innovations in Cancer (Basic) Research
The 5th Edition of the Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) will bring together leading experts in cancer research, healthcare, and policy from Central and Eastern Europe (CEE) and the United States and Canada. The OECI involved is specially with integration of OECI Members in CEE. The symposium aims to foster international collaboration, share cutting-edge research, and drive innovation in cancer prevention, treatment, and care.
This year’s theme, „Innovating Together to Conquer Cancer Globally”, will explore emerging trends, challenges, and opportunities in oncology, with a particular focus on policy innovation, global health initiatives, artificial intelligence, precision medicine, and biotech-academia partnerships. (OECI)
Day 1 – September 3, 2025
Public Health & AI Innovations in Oncology
- Innovative Public Health Policies
Developing and implementing new policies to enhance cancer prevention, and screening accessibility; - Global Health Initiatives
Addressing cancer disparities worldwide, improving healthcare access in underserved population by fostering global collaborations; - Data and AI in oncology
Utilizing AI for early detection, personalized treatment, and enhanced patient outcomes.
Day 2 – September 4, 2025
Breakthroughs in Oncology
& Oncology Collaboration
- Immunotherapy
Advancements in immunotherapy and clinical trials; - Precision Medicine
Advancements in targeted cancer therapies through clinical trials; - Academia-HealthCare-Biotech Collaboration
Overcoming challenges in research partnerships: Bridging Science, Policy and Industry.
Day 3 – September 5, 2025
Emerging Innovations in Cancer (Basic) Research
- Functional Precision Oncology
Keynote addresses and panel discussions on future directions in oncology; - Tumor Immuno MicroEnvironment.
Program of the Symposium
Please expand section below to find general program of the conference. We will share more details at a later time.
Day 1 – September 3, 2025 | Public Health & AI Innovations in Oncology
Session 1: Innovative Public Health Policies
Developing and implementing new policies to enhance cancer prevention, and screening accessibility.
Session Chairs: Pawel Koczkodaj (Poland), Anda Vlad or Phillip Castle (USA/NCCN)
⏳ Duration: 2.5 hours
9:00 – 11:30
Session 2: Global Health Initiatives
Addressing cancer disparities worldwide, improving healthcare access in underserved population by fostering global collaborations.
Session Chairs: Iwona Lugowska (Poland), Thierry Philip / Claudio Lombardo (OECI WORLD), USA Representative
- OECI – Ensuring Quality Through Accreditation
- CCI4EU – How to Build Capacity
- Use Cases and Our Deep Dives: Three Countries – Croatia, Piedmont, and Poland
- Discussions
⏳ Duration: 2.5 hours
12:30 – 15:00
Session 3: Data and AI in oncology
Utilizing AI for early detection, personalized treatment, and enhanced patient outcomes.
Session Chairs: Magdalena Rosinska (Poland), with USA and CEE Representative
⏳ Duration: 2.5 hours
15:30 – 17:30
Day 2 – September 4, 2025 | Breakthroughs in Oncology & Oncology Collaboration
Session 1: Immunotherapy
Advancements in immunotherapy and clinical trials.
Session Chairs: Piotr Rutkowski (Poland), USA Representative: Tom Gajewski
| Welcome and Introduction – Piotr Rutkowski and Tom Gajewski | 09:00-09:05 |
| 1. Kalinski P. Chemokine – Modulating Regimen (CKM; Rintatolimod plus IFNa) in Patient with Solid Tumors Patients Reprograms “Cold” Tumors for Enhanced CTL Influx (no6) | 09:05-09:20 |
| 2. Kokolus K. Chemokine Modulation (CKM): Sensitizing the Tumor Microenvironment to PD-1 Blockade with a TLR-3 ligand and Type-I IFN Combinatorial Approach (no19) | 09:20-09:35 |
| 3. Iwański M. Cardiological predictors of balstilimab efficacy in the treatment of non-melanoma skin cancers: Results from the AGENONMELA phase II trial (no23) | 09:35-09:50 |
| 4. Zelwiańska A. Anti-GD2 Immunotherapy in Ewing Sarcoma: Preliminary Data from the Butterfly Project (no12) | 09:50-10:05 |
| Q&A | 10:05-10:15 |
| 5. Kalinski P. Dendritic Cells in Cancer Immunotherapy: Vaccines, Live Adjuvants and T Cell Therapies with DC-sensitized T Cells (no9) | 10:15-10:30 |
| 6. Griffiths E. THE IMMUNE MICROENVIRONMENT IN MYELODYSPLATIC SYNDROMES (no20) | 10:30-10:45 |
| 7. Switzer B. D3 Tumor Immuno MicroEnvironment (no37) | 10:45-11:00 |
| 8. Czarniecki B. Intratumoral delivery of conventional dendritic cells pulsed with MHC class II peptides and alpha-galactosyl-ceramide leads to eradication of disseminated cancer cells. (no65) | 11:00-11:15 |
| Q&A and closing remarks | 11:15-11:30 |
⏳ Duration: 2.5 hours
9:00 – 11:30
Session 2: Precision Medicine
Advancements in targeted cancer therapies through clinical trials.
Session Chairs: Iwona Lugowska (Poland), USA Representative
- Molecular and immunological classification of chondrosarcoma. Prof. Piotr Rutkowski
⏳ Duration: 2.5 hours
Session 3: Academia-HealthCare-Biotech Collaboration
Overcoming challenges in research partnerships: Bridging Science, Policy and Industry.
Session Chairs: Wojciech Fendler (Poland), Paweł Kalinski (USA Representative), Piotr Widłak (Poland)
⏳ Duration: 2.5 hours
Day 3 – September 5, 2025 | Emerging Innovations in Cancer (Basic) Research
Session 1: Functional Precision Oncology
Keynote addresses and panel discussions on future directions in oncology.
Session Chairs: Michal Mikula (MSCI), Alana Welm (University of Utah, USA)
| Welcome and Introduction- Michał Mikula, MSCI | 09:00-09:05 |
| Keynote US / Alana Welm, PhD – “Modeling metastatic breast cancer to advance therapeutic strategies”, University of Utah | 09:05-09:35 |
| PL / Andrzej Mazan, PhD – “Exploring Synthetic Lethality and novel drug combinations in Patient-Derived Cells”, Ryvu Therapeutics | 09:35-09:55 |
| PL / Dawid Walerych – “Driver oncogene cooperation and competition in cancer”, Mossakowski Medical Research Institute PAS | 09:55-10:15 |
| BE / Agnieszka Wozniak, PhD „Xenosarc: A Panel of Patient-Derived Xenograft Models of Sarcoma for Preclinical Drug Evaluation” Leuven Cancer Institute | 10:15-10:35 |
| PL / Maria Mazur – “AD-O51.4 – harnessing the power of natural apoptosis”, ADAMED | 10:35-10:55 |
| PL / Jaroslaw Cendrowski, PhD “Development of high-content screening (HCS)-based methodology for the purpose of functional precision oncology.” | 10:55-11:05 |
| LT / Agata Mlynska “Modelling immune-excluded tumors in murine breast cancer models using 3D spheroid injections” | 11:05-11:15 |
| Discussion and closing remars | 11:15-11:30 |
⏳ Duration: 2.5 hours
9:00 – 11:30
Session 2: Tumor Immuno MicroEnvironment
Session Chairs: Elżbieta Sarnowska (Poland), Marcin Kortylewski (USA)
- Natalia Khranowska – title pending, Ukraine
- Alfonso Urbanucci – “Prostate cancer immune microenvironment”, Oslo, Norway
- Leszek Kotula – “ABI1 in T cell function – pending”, Upstate US
- Andreas Pearl – Upstate, USA
⏳ Duration: 2.5 hours
12:30 – 15:00